The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
Amides
Analgesics
/ pharmacology
Animals
Anti-Inflammatory Agents
/ pharmacology
Apoptosis
/ drug effects
Cytokines
/ metabolism
Diabetic Neuropathies
/ drug therapy
Disease Models, Animal
Ethanolamines
/ pharmacology
Hyperalgesia
/ drug therapy
Inflammation
/ drug therapy
Male
Mice
NF-kappa B
/ metabolism
Neovascularization, Pathologic
/ drug therapy
Neuroprotective Agents
/ pharmacology
Nitrosative Stress
/ drug effects
Oxidative Stress
/ drug effects
Pain
/ drug therapy
Palmitic Acids
/ pharmacology
Sciatic Nerve
/ drug effects
Signal Transduction
/ drug effects
DPN
PPAR-α
neuroinflammation
oxidative stress
pain
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
26
7
2019
medline:
26
5
2020
entrez:
26
7
2019
Statut:
ppublish
Résumé
Diabetic peripheral neuropathy (DPN) is a complication of diabetes connected with morbidity and mortality. DPN presents deterioration of peripheral nerves with pain, feebleness, and loss of sensation. Particular medications might display their remedial potential by controlling neuroinflammation. Palmitoylethanolamide (PEA) is an autacoid local injury antagonist distinguished for its neuroprotective, analgesic, and anti-inflammatory properties in numerous experimental models of neuroinflammation. Based on these findings, the goal of this work was to better test the neuroprotective effects of a formulation of micronized PEA (PEA-m) and the probable mechanism of action in a mouse model of DPN induced by streptozotocin (STZ) injection. Diabetic and control animals received PEA-m (10 mg/kg) by oral gavage daily starting 2 wk from STZ injection. After 16 wk, the animals were euthanized, and blood, urine, spinal cord, and sciatic nerve tissues were collected. Our results demonstrated that after diabetes induction, PEA-m was able to reduce mechanical, thermal hyperalgesia, and motor alterations as well as reduce mast cell activation and nerve growth factor expression. In addition, PEA-m decreased neural histologic damage, oxidative and nitrosative stress, cytokine release, angiogenesis, and apoptosis. Moreover, spinal microglia activation (IBA-1), phospho-P38 MAPK, and nuclear factor NF-κB inflammatory pathways were also inhibited. The protective effects of PEA-m could be correlated at least in part to peroxisome proliferator-activated receptor-α activation. In summary, we demonstrated that PEA-m represents a new therapeutic strategy for neuroinflammation pain associated with mixed neuropathies.-Impellizzeri, D., Peritore, A. F., Cordaro, M., Gugliandolo, E., Siracusa, R., Crupi, R., D'Amico, R., Fusco, R., Evangelista, M., Cuzzocrea, S., Di Paola, R. The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
Identifiants
pubmed: 31344333
doi: 10.1096/fj.201900538R
doi:
Substances chimiques
Amides
0
Analgesics
0
Anti-Inflammatory Agents
0
Cytokines
0
Ethanolamines
0
NF-kappa B
0
Neuroprotective Agents
0
Palmitic Acids
0
palmidrol
6R8T1UDM3V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM